Biomarkers in Relation to Cognitive Reserve in Patients with Mild Cognitive Impairment – Proof of Concept

Background: The concept of the cognitive reserve (CR) posits that factors such as education enable compensation for the effect of brain pathology. Consequently, pathology should be more pronounced in individuals with higher CR before becoming clinically apparent. Biomarkers such as total tau (t-tau) and β-amyloid 42 (Aβ42) may be surrogates for pathology in relation to CR in patients with neurodegenerative disease. Objective: To examine the applicability of biomarkers as surrogates for pathology in relation to the CR in patients with mild cognitive impairment (MCI) either converting to dementia or remaining stable at follow-up. Method: Comparisons of baseline t-tau, Aβ42, educational years and global cognition for MCI patients either converting to dementia (n = 57) or remaining stable (n = 91) were made. Patients converting to dementia were grouped on the basis of educational level and compared considering biomarkers and neuropsychological tests. Results: Stable MCI patients were better educated, performed better cognitively, had higher Aβ42 levels and lower levels of t-tau. Converting MCI patients with higher education had lower levels of Aβ42 and performed equally in neuropsychological tests compared to those with lower education. Conclusion: Our results suggest that highly educated MCI patients subsequently converting to dementia display more amyloid pathology.

[1]  M. Viitanen,et al.  Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease , 2008, Annals of neurology.

[2]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[3]  Y. Stern What is cognitive reserve? Theory and research application of the reserve concept , 2002, Journal of the International Neuropsychological Society.

[4]  Richard Mayeux,et al.  Epidemiology of neurodegeneration. , 2003, Annual review of neuroscience.

[5]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[6]  Pieter Visser,et al.  Faculty Opinions recommendation of Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. , 2006 .

[7]  M. Albert,et al.  Predictors of cognitive change in older persons: MacArthur studies of successful aging. , 1995, Psychology and aging.

[8]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[9]  A. Hofman,et al.  Rates and risk factors for dementia and Alzheimer’s disease , 1999, Neurology.

[10]  R. Sperling,et al.  Use of IQ-adjusted norms to predict progressive cognitive decline in highly intelligent older individuals. , 2004, Neuropsychology.

[11]  Bruce G. Link,et al.  Relationship between lifetime occupation and parietal flow , 1995, Neurology.

[12]  J. Morris,et al.  Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.

[13]  G. Alexander,et al.  Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease , 1992, Annals of neurology.

[14]  Yaakov Stern,et al.  Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis. , 2003, Archives of neurology.

[15]  S. Black,et al.  Evidence from Functional Neuroimaging of a Compensatory Prefrontal Network in Alzheimer's Disease , 2003, The Journal of Neuroscience.

[16]  K. Blennow,et al.  Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. , 2007, Journal of Alzheimer's disease : JAD.

[17]  D. Royall,et al.  Bedside Assessment of Executive Cognitive Impairment: The Executive Interview , 1992, Journal of the American Geriatrics Society.

[18]  T. Grabowski Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease , 2008 .

[19]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[20]  D. Bennett,et al.  Education modifies the association of amyloid but not tangles with cognitive function , 2005, Neurology.

[21]  R. Mayeux,et al.  Influence of education and occupation on the incidence of Alzheimer's disease. , 1994, JAMA.

[22]  Sebastiaan Engelborghs,et al.  No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. , 2007, Brain : a journal of neurology.

[23]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[24]  J. Teresi,et al.  Reading ability, education, and cognitive status assessment among older adults in Harlem, New York City. , 1999, American journal of public health.

[25]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[26]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[27]  H Morgenstern,et al.  Development of dementing illnesses in an 80‐year‐old volunteer cohort , 1989, Annals of neurology.

[28]  K. Blennow,et al.  Stepwise Comparative Status Analysis (STEP): A Tool for Identification of Regional Brain Syndromes in Dementia , 1996, Journal of geriatric psychiatry and neurology.

[29]  K. Blennow,et al.  Aspects of beta-amyloid as a biomarker for Alzheimer's disease. , 2007, Biomarkers in medicine.

[30]  K. Blennow CSF biomarkers for mild cognitive impairment , 2004, Journal of internal medicine.

[31]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[32]  D. Bennett,et al.  Processing resources reduce the effect of Alzheimer pathology on other cognitive systems , 2008, Neurology.

[33]  Y. Stern Cognitive Reserve and Alzheimer Disease , 2006, Alzheimer disease and associated disorders.

[34]  Jean-François Dartigues,et al.  The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. , 2005, Brain : a journal of neurology.

[35]  A. Wallin,et al.  The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[36]  M. Albert,et al.  Predictors of cognitive change in older persons: MacArthur studies of successful aging. , 1995, Psychology and aging.

[37]  A. Wallin,et al.  The Swedish National Adult Reading Test (NART-SWE): a test of premorbid IQ. , 2008, Scandinavian journal of psychology.

[38]  Christine Van Broeckhoven,et al.  No association of CSF biomarkers with APOEε4, plaque and tangle burden in definite Alzheimer's disease , 2007 .

[39]  K. Blennow,et al.  Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI , 2008, Journal of the International Neuropsychological Society.

[40]  Y. Stern,et al.  Education and rates of cognitive decline in incident Alzheimer’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[41]  Lippincott Williams Wilkins,et al.  Assessment: neuropsychological testing of adults. Considerations for neurologists. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. , 1996, Neurology.

[42]  P Pietrini,et al.  Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. , 1997, The American journal of psychiatry.

[43]  KennethRockwood,et al.  The Canadian Study of Health and Aging* , 1994, Neurology.

[44]  Kaj Blennow,et al.  Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.